CRISPR, Patents, and the Public Health

Yale Journal of Biology and Medicine, vol. 90, pp. 667-672 (2017)

NYLS Legal Studies Research Paper No. 3093610

6 Pages Posted: 3 Jan 2018 Last revised: 28 Jan 2018

See all articles by Jacob S. Sherkow

Jacob S. Sherkow

University of Illinois College of Law; Center for Advanced Studies in Biomedical Innovation Law

Date Written: December 17, 2017

Abstract

Patent issues surrounding CRISPR, the revolutionary genetic editing technology, may have important implications for the public health. Patents maintain high prices for novel therapies, limiting patient access. Relatedly, insurance coverage for expensive therapies is waning. Patents also misallocate research and development resources to profitable disease indications rather than those that necessarily impinge on the public health. And it is unclear how CRISPR therapies will figure into the current regulatory framework for biosimilars. Policy makers and physicians should consider these issues now, before CRISPR therapies become widely adopted—and entrenched—in the marketplace.

Keywords: crispr, patents, public health, gene editing, drug pricing, insurance, research, regulation, law, policy

JEL Classification: K00, K11, O3, O34

Suggested Citation

Sherkow, Jacob S., CRISPR, Patents, and the Public Health (December 17, 2017). Yale Journal of Biology and Medicine, vol. 90, pp. 667-672 (2017), NYLS Legal Studies Research Paper No. 3093610, Available at SSRN: https://ssrn.com/abstract=3093610

Jacob S. Sherkow (Contact Author)

University of Illinois College of Law ( email )

504 E. Pennsylvania Avenue
Champaign, IL 61820
United States

Center for Advanced Studies in Biomedical Innovation Law ( email )

Studiestraede 6
Studiestrade 6
Copenhagen, DK-1455
Denmark

HOME PAGE: http://jura.ku.dk/cebil/staff/

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
183
Abstract Views
1,127
rank
180,059
PlumX Metrics